Compare Glenmark Pharma with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs CIPLA - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA CIPLA GLENMARK PHARMA/
CIPLA
 
P/E (TTM) x 12.8 27.0 47.5% View Chart
P/BV x 1.9 3.8 50.6% View Chart
Dividend Yield % 0.5 0.6 89.7%  

Financials

 GLENMARK PHARMA   CIPLA
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-21
CIPLA
Mar-21
GLENMARK PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs573879 65.2%   
Low Rs195411 47.6%   
Sales per share (Unadj.) Rs387.8237.6 163.3%  
Earnings per share (Unadj.) Rs34.429.8 115.5%  
Cash flow per share (Unadj.) Rs50.143.0 116.5%  
Dividends per share (Unadj.) Rs2.505.00 50.0%  
Avg Dividend yield %0.70.8 83.9%  
Book value per share (Unadj.) Rs249.6226.7 110.1%  
Shares outstanding (eoy) m282.17806.46 35.0%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x1.02.7 36.5%   
Avg P/E ratio x11.221.6 51.6%  
P/CF ratio (eoy) x7.715.0 51.1%  
Price / Book Value ratio x1.52.8 54.1%  
Dividend payout %7.316.8 43.3%   
Avg Mkt Cap Rs m108,353519,826 20.8%   
No. of employees `000NANA-   
Total wages/salary Rs m23,43732,518 72.1%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m109,439191,596 57.1%  
Other income Rs m5022,698 18.6%   
Total revenues Rs m109,941194,294 56.6%   
Gross profit Rs m21,28942,487 50.1%  
Depreciation Rs m4,43610,677 41.5%   
Interest Rs m3,5311,607 219.7%   
Profit before tax Rs m13,82532,901 42.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m4,1248,888 46.4%   
Profit after tax Rs m9,70124,013 40.4%  
Gross profit margin %19.522.2 87.7%  
Effective tax rate %29.827.0 110.4%   
Net profit margin %8.912.5 70.7%  
BALANCE SHEET DATA
Current assets Rs m73,596132,095 55.7%   
Current liabilities Rs m42,01045,916 91.5%   
Net working cap to sales %28.945.0 64.2%  
Current ratio x1.82.9 60.9%  
Inventory Days Days768 9.8%  
Debtors Days Days867 1,306.8%  
Net fixed assets Rs m67,093116,277 57.7%   
Share capital Rs m2821,613 17.5%   
"Free" reserves Rs m70,148181,232 38.7%   
Net worth Rs m70,430182,844 38.5%   
Long term debt Rs m38,88812,028 323.3%   
Total assets Rs m140,689248,372 56.6%  
Interest coverage x4.921.5 22.9%   
Debt to equity ratio x0.60.1 839.4%  
Sales to assets ratio x0.80.8 100.8%   
Return on assets %9.410.3 91.2%  
Return on equity %13.813.1 104.9%  
Return on capital %15.917.7 89.7%  
Exports to sales %031.3 0.0%   
Imports to sales %010.9 0.0%   
Exports (fob) Rs mNA59,951 0.0%   
Imports (cif) Rs mNA20,911 0.0%   
Fx inflow Rs m35,75368,051 52.5%   
Fx outflow Rs m12,02320,911 57.5%   
Net fx Rs m23,72947,140 50.3%   
CASH FLOW
From Operations Rs m11,31237,552 30.1%  
From Investments Rs m-6,752-23,872 28.3%  
From Financial Activity Rs m-4,418-13,299 33.2%  
Net Cashflow Rs m278509 54.6%  

Share Holding

Indian Promoters % 46.7 14.3 325.8%  
Foreign collaborators % 0.0 21.8 -  
Indian inst/Mut Fund % 35.0 45.9 76.4%  
FIIs % 24.2 24.4 99.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 53.4 63.9 83.5%  
Shareholders   317,383 451,365 70.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   SUN PHARMA    LUPIN    AUROBINDO PHARMA    DR. REDDYS LAB    CADILA HEALTHCARE    



Today's Market

Sensex Sheds 427 Points, Nifty Ends Near 17,600; Bajaj Finserv, Tata Steel & Tech Mahindra Top Losers(Closing)

Indian share markets witnessed negative trading activity throughout the day today and ended on a weak note.

Related Views on News

CIPLA 2020-21 Annual Report Analysis (Annual Result Update)

Oct 20, 2021 | Updated on Oct 20, 2021

Here's an analysis of the annual report of CIPLA for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

GLENMARK PHARMA 2020-21 Annual Report Analysis (Annual Result Update)

Sep 6, 2021 | Updated on Sep 6, 2021

Here's an analysis of the annual report of GLENMARK PHARMA for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

5 Indian Pharma Companies Riding the Vaccination Wave (Views On News)

Sep 3, 2021

These companies are likely to benefit the most from Covid-19 vaccines.

What's Behind the Rally in Pharma Stocks? (Views On News)

May 11, 2021

The second wave of Covid has given a new lease of life to pharma stocks.

More Views on News

Most Popular

10 Indian Companies with the Fastest Growth in Dividend Payouts...(Views On News)

Jan 10, 2022

These companies have been consistently paying higher dividends for several years.

Tata Steel vs SAIL: Which Stock is Better?(Views On News)

Jan 13, 2022

With government initiatives set to boost the steel sector, find out who has a better chance of coming out on top.

Watch Out for these 4 Indian Companies Betting Big on EV Supply Chain(Views On News)

Jan 11, 2022

The upside in supply chain players could be huge but a delay in the transition to EVs, or any policy related hiccups could end the momentum.

Tech Mahindra's CTC Acquisition: Too Expensive?(Views On News)

Jan 18, 2022

Tech Mahindra's acquisition of European IT-company fails to excite investors.

Time to Buy Energy Stocks(Fast Profits Daily)

Jan 14, 2022

Energy is a sector that looks set to take off. It's time to get in.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Jan 21, 2022 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS